Company Announcement - Jazz Pharmaceuticals plc will report its 2025 second quarter financial results on August 5, 2025, after the U.S. financial markets close [1] - A live audio webcast will be hosted by company management at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the financial results and provide a business update [1] Registration and Replay Information - Interested parties can register for the call in advance through the Investors section of the Jazz Pharmaceuticals website [2] - It is recommended that participants register at least 15 minutes prior to the scheduled webcast to ensure a timely connection [2] - A replay of the webcast will be available on the Investors section of the Jazz Pharmaceuticals website [2] Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on innovating to transform the lives of patients with serious diseases [3] - The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders, epilepsy, and a growing portfolio of cancer treatments [3] - Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories and manufacturing facilities in multiple countries [3]

Core Points - Idorsia Ltd has announced the date for its Annual General Meeting (AGM) to be held on May 28, 2025, to approve the Annual Report for the year ending December 31, 2024 [1] - The Chairman of the Board, Jean-Paul Clozel, expressed gratitude towards the Board members and noted that Dr. Sophie Kornowski will not seek re-election, while all other members will stand for re-election [2] - The company aims to amend its Articles of Association regarding share capital to enhance financing flexibility [2] Company Overview - Idorsia Ltd is focused on discovering, developing, and commercializing transformative medicines, with a strong scientific core and a commitment to challenging accepted medical paradigms [6][8] - The company is headquartered near Basel, Switzerland, and is positioned within a European biotech hub, emphasizing its capabilities in drug discovery, particularly in small-molecule drugs [7][8] AGM Agenda Highlights - The AGM will include votes on the Annual Report 2024, Consolidated Financial Statements 2024, and Statutory Financial Statements 2024 [7] - Other key agenda items include the appropriation of available earnings, discharge of the Board of Directors, amendments to share capital, and re-elections of Board members and statutory auditors [7]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on April 29, 2025, to discuss its first quarter 2025 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call is scheduled for April 29, 2025, at 8:30 a.m. Eastern Time [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website approximately 48 hours after the call [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company aims to discover, acquire, develop, and commercialize novel therapies for diseases with unmet needs [3]. - Kiniksa's portfolio is based on strong biological rationale and validated mechanisms, offering potential for differentiation in the market [3].